Company Description
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.
The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022.
Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2013 |
| IPO Date | May 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 274 |
| CEO | Vladimir Coric |
Contact Details
Address: 215 Church Street New Haven, Connecticut 06510 United States | |
| Phone | 203 404 0410 |
| Website | biohaven.com |
Stock Details
| Ticker Symbol | BHVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001935979 |
| CUSIP Number | G11196105 |
| ISIN Number | VGG1110E1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladimir Coric M.D. | Chairman and Chief Executive Officer |
| Matthew Buten | Chief Financial Officer |
| Dr. Bruce D. Car DACVP, Ph.D. | Chief Scientific Officer |
| Kimberly Gentile | Senior Vice President of Clinical Operations |
| Deb Young | Senior Director of Regulatory Affairs and Operations |
| George C. Clark CPA | Vice President and Chief Accounting Officer |
| John McGill | Chief Technology Officer |
| Jennifer Porcelli | Vice President of Investor Relations |
| Warren Volles J.D. | General Counsel and Chief Legal Officer |
| Clifford Bechtold M.S. | President and GM of Biohaven Ireland Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 13, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 2, 2026 | 8-K | Current Report |
| Mar 2, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 2, 2026 | 10-K | Annual Report |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 6, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Jan 7, 2026 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G | Filing |